Visceral Angioedema caused by Angiotensin Receptor Blocker


Visceral Angioedema caused by Angiotensin Receptor Blocker


Arun Minupuri, Roshni Patel, Jesus Salas Noain

Mercy Catholic Medical Center


International-Journal-of-Case-Reports-2d code

In literature we see clear evidence of Angiotensin Converting Enzyme inhibitors (ACEI’s) causing visceral angioedema, but further evidence is required to establish the causality for Angiotensin Receptor Blockers (ARB’s). With the widespread usage of these anti-hypertensives and the potential serious adverse effect in the form of angioedema; clinicians should consider medication induced as part of their differentials.


Keywords: Visceral Angioedema, Angiotensin Receptor Blocker


Free Full-text PDF


How to cite this article:

Arun Minupuri, Roshni Patel, Jesus Salas Noain. Visceral Angioedema caused by Angiotensin Receptor Blocker. International Journal of Case Reports, 2020 4:144. DOI: 10.28933/ijcr-2020-06-2605


References:

1. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998;18(3):171-188. doi:10.2165/00002018-199818030-00003
2. Gibbs CR, Lip GY, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol. 1999;48(6):861-865. doi:10.1046/j.1365-2125.1999.00093.x
3. Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 2003;16(1):123-126. doi:10.1080/08998280.2003.11927893
4. Thalanayar PM, Ghobrial I, Lubin F, Karnik R, Bhasin R. Drug-induced visceral angioedema. J Community Hosp Intern Med Perspect. 2014;4(4):10.3402/jchimp.v4.25260. Published 2014 Sep 29. doi:10.3402/jchimp.v4.25260
5. Tadevosyan A, Maclaughlin EJ, Karamyan VT. Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. Patient Relat Outcome Meas. 2011;2:27-39. doi:10.2147/PROM.S8384
6. Sobotková M. Angiotensin-converting enzyme inhibitor-induced angioedema: epidemiology, pathogenesis and management. Angioedém indukovaný inhibitory enzymu konvertujícího angiotenzin: epidemiologie, patogeneze a léčba. Vnitr Lek. 2018;64(10):928-933.